Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metvix photodynamic therapy simplified versus approved regimen in low-risk basal cell carcinoma
2011-004797-28Phase 4Completed
- Sponsor
- Norwegian University of Science and Technology
- Start
- Mar 2012
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of methyl aminolevulinate in basal cell carcinoma (BCC) (2 arms), sponsored by Norwegian University of Science and Technology. Primary endpoint: Lesion cure rate and cosmetic outcome. Started Mar 2012; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2011-004797-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004797-28.